این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
مجله پزشکی ارومیه، جلد ۱۸، شماره ۵، صفحات ۲۵-۲۸
عنوان فارسی بررسی پلی مورفیسم ژن های CYP۳A۵، MDR۱ و ارتباط آن با غلظت خونی سیکلوسپورین در مراحل اولیه بعد از پیوند کلیه در بیماران شیراز
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله سیکلوسپورین - پیوند کلیه، 3A5 CPY، MDR، پلی مورفیسم
عنوان انگلیسی GENETIC POLYMORPHISMS OF CYP3A5 AND MDR1 ON CYCLOSPORINE CONCENTRATION IN THE EARLY STAGE AFTER RENAL TRANSPLANTATION
چکیده انگلیسی مقاله Background & Aims: The immunosuppressive drug cyclosporine with a narrow therapeutic range and variable pharmacokinetic characteristics among individuals is a substrate for cytochrome P450 (CYP) 3A and P-glycoprotein, the product of the multidrug resistance 1 (MDR1) gene. Some of the single nucleotide polymorphisms (SNPs) in these genes are associated with deficient protein expression and reduced in vivo activity. We postulated that, in renal transplant recipients, these SNPs could be associated with interindividual variations in cyclosporine pharmacokinetics. Materials & Methods: CYP3A5 and MDR1 genotypes were determined by polymerase chain reaction followed by restriction fragment length polymorphism analysis in 88 Iranian renal transplant patients receiving cyclosporine. Whole blood trough cyclosporine concentration was measured by radioactive immunosorbent assay and dose-adjusted concentration (ng/mL per mg/kg/d) was calculated at 1 to 3 days, 1 week, and 1 month after transplantation. Results: The MDR-1 wild -type genotype (3435CC) was observed in 17 patients (19 %), whereas 45 (51%) patients were heterozygous (3435CT), and 26 (30%) patients were homozygous (3435 TT) for the mutation. In early days after transplantation, we found a correlation between the concentration/dose ratio and exon 26 MDR SNP (33.3±15.24 in the CT group vs. 44.1±28.4 [µg mg/L/kg] in the TT group, P=0.019). This ratio was significantly higher in subjects homozygous for the mutation (3435TT). This significant difference was not seen in 1 week and 1 month after transplantation. Accordingly, in this study all patients had CYP3A5*3/*3 genotype, so we could not find any differences among the CYP3A5*1/*3 genotypes. Conclusion: MDR-1 (3435CC) polymorphisms are associated with cyclosporine pharmacokinetics and dose requirements in renal transplant recipients. Pharmacokinetic methods could be employed to help initial dose selection and to individualize immunosuppressive therapy. But it is important to say that one of the reasons that our population showed drug toxicity with lower dose of drug due to this genetic polymorphism at Cyp3A5 is that the drug couldn't be metabolized correctly and fast. So Iranian population need lower dose of cyclosporine .
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله نگار آذرپیرا |
مرکز تحقیقات پیوند اعضاء، بیمارستان نمازی شیراز، دانشگاه علوم پزشکی شیراز تلفن 6276211-0711 فاکس 6276211-0711
سازمان اصلی تایید شده: دانشگاه علوم پزشکی شیراز (Shiraz university of medical sciences)

علی ملک حسینی |


سعید بهزادی |


نشانی اینترنتی http://umj.umsu.ac.ir/browse.php?a_code=A-10-1-229&slc_lang=fa&sid=fa
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده fa
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده 1
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات